Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook


CRISPR success in repairing sickle-cell anaemia mutation

17 October 2016

By Sarah Gregory

Appeared in BioNews 873

Researchers have used the CRISPR/Cas9 genome-editing technique to correct the mutation that causes sickle-cell anaemia.

The researchers used a modified version of the technique to correct the mutation in human bone-marrow stem cells. They were able to show that these edited healthy cells could survive long term in mice at a level that may be high enough to benefit human patients.

'We're very excited about the promise of this technology,' said Jacob Corn, a senior author on the study and scientific director of the Innovative Genomics Initiative, which conducted the joint study between University of California, Berkeley, and the University of California San Francisco (UCSF). 'There is still a lot of work to be done before this approach might be used in the clinic, but we're hopeful that it will pave the way for new kinds of treatment for patients with sickle-cell disease.'

Sickle-cell anaemia is caused by a single mutation in the gene that codes for haemoglobin protein. This mutation causes the characteristic 'sickle-shaped' blood cells which cause blockages in blood vessels, pain, and organ failure.

There have been previous attempts to use CRISPR/Cas9 to remove the mutated sickle-cell gene and insert a correct version of the gene into the bone-marrow stem cells. However, gene insertion is often unsuccessful in these slow-dividing stem cells.

The research team modified the existing genome-editing process by adding an additional DNA sequence tag. This increased the efficiency of the gene repair by up to 25 percent.

They then infused mice with one million edited cells to test if the healthy gene would be maintained long term. Although cells with mutated DNA were more successful at proliferating, after 16 weeks an average of 2.3 percent of the edited cells remained in five mice. 

Although this is a low percentage, evidence suggests that even this small change can have a positive effect on a person with the disease.

'This is an important advance because for the first time we show a level of correction in stem cells that should be sufficient for a clinical benefit in persons with sickle-cell anaemia,' said co-author Dr Mark Walters, a paediatric haematologist and oncologist and director of UCSF Benioff Oakland’s Blood and Marrow Transplantation Program.

Other scientists caution that this level may not be sufficient. 'This is an important incremental step in bringing this sort of gene therapy to the clinic, but you need a little higher rate of correction to make it a therapy that is likely to be successful,’ Dr John Strouse, a haematologist at Duke University who was not involved in the study, told the Los Angeles Times.

The researchers say that years of study will be needed before the genome-editing could be safely introduced in humans.

The study was published in the current issue of Science Translational Medicine.

STAT | 12 October 2016
Nature News | 12 October 2016
University of California, Berkeley (press release) | 12 October 2016
Science Translational Medicine | 12 October 2016
Los Angeles Times | 12 October 2016


26 June 2017 - by Meghna Kataria 
Eliminating the faulty protein that causes Huntingdon's disease goes some way to reversing disease progression in mice, a study has found...
06 March 2017 - by Ayala Ochert 
A teenage boy in France appears to have been cured of sickle cell disease using a gene therapy. He has been free of all signs of the disease for 15 months...
09 January 2017 - by Dr Özge Özkaya 
Scientists have discovered a new set of proteins that can block the CRISPR/Cas9 system...
14 November 2016 - by Sarah Gregory 
Researchers have had further success using the CRISPR/Cas9 genome-editing technique to repair the mutation that causes sickle-cell anaemia...
14 November 2016 - by Dr Avi Lerner 
Jewish bioethics may help to broaden the discussion of the ethical concerns that emerge from editing the human genome...

12 September 2016 - by Dr Özge Özkaya 
Scientists from China have managed to shrink the size of tumours in mice using CRISPR/Cas9 genome-editing technology...
12 September 2016 - by Dr Nicoletta Charolidi 
A genetically engineered virus that triggers the production of an alternative form of haemoglobin has reversed the symptoms of sickle cell disease in mice...
27 June 2016 - by Rachel Reeves 
The first in-human use of the genome-editing technology CRISPR has been approved by a US federal safety board...
11 April 2016 - by James Brooks 
Scientists testing whether the CRISPR genome-editing technique could effectively kill HIV in infected cells have found that, while the approach works in most cases, it can also cement the virus's presence...
17 October 2011 - by Mehmet Fidanboylu 
The blood condition sickle cell disease may be reversed by turning off a single gene, according to scientists in the USA. By inactivating a single gene in red blood cells the researchers were able to alleviate symptoms of the disease in mice, offering the hope of a potential new treatment for humans...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation